
    
      A 12 month open-label randomized parallel group study to investigate the influence of
      salmeterol xinafoate/fluticasone propionate either in fixed combination (SFC50/500 µg bid) or
      separately (SAL 50 µg and FP 500 µg bid) via Diskus inhalers on the course of the disease and
      frequency of exacerbations in subjects with severe and very severe COPD ( GOLD stage III+IV)
    
  